Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model

  • Park, Hee Sun (Department of Radiology, Konkuk University School of Medicine) ;
  • Han, Joon Koo (Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Lee, Jeong Min (Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Kim, Young Il (Department of Radiology, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab Emirates) ;
  • Woo, Sungmin (Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital) ;
  • Yoon, Jung Hwan (Department of Internal Medicine, Seoul National University Hospital) ;
  • Choi, Jin-Young (Department of Radiology, Yonsei University College of Medicine) ;
  • Choi, Byung Ihn (Department of Radiology and Institute of Radiation Medicine, Seoul National University Hospital)
  • Received : 2015.02.27
  • Accepted : 2015.05.18
  • Published : 2015.09.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using macromolecular contrast agent (P792) for assessment of vascular disrupting drug effect in rabbit VX2 liver tumor models. Materials and Methods: This study was approved by our Institutional Animal Care and Use Committee. DCE-MRI was performed with 3-T scanner in 13 VX2 liver tumor-bearing rabbits, before, 4 hours after, and 24 hours after administration of vascular disrupting agent (VDA), using gadomelitol (P792, n = 7) or low molecular weight contrast agent (gadoterate meglumine [Gd-DOTA], n = 6). P792 was injected at a of dose 0.05 mmol/kg, while that of Gd-DOTA was 0.2 mmol/kg. DCE-MRI parameters including volume transfer coefficient (Ktrans) and initial area under the gadolinium concentration-time curve until 60 seconds (iAUC) of tumors were compared between the 2 groups at each time point. DCE-MRI parameters were correlated with tumor histopathology. Reproducibility in measurement of DCE-MRI parameters and image quality of source MR were compared between groups. Results: P792 group showed a more prominent decrease in Ktrans and iAUC at 4 hours and 24 hours, as compared to the Gd-DOTA group. Changes in DCE-MRI parameters showed a weak correlation with histologic parameters (necrotic fraction and microvessel density) in both groups. Reproducibility of DCE-MRI parameters and overall image quality was not significantly better in the P792 group, as compared to the Gd-DOTA group. Conclusion: Dynamic contrast-enhanced magnetic resonance imaging using a macromolecular contrast agent shows changes of hepatic perfusion more clearly after administration of the VDA. Gadolinium was required at smaller doses than a low molecular contrast agent.

Keywords

References

  1. Delrue LJ, Casneuf V, Van Damme N, Blanckaert P, Peeters M, Ceelen WP, et al. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. MAGMA 2011;24:225-232 https://doi.org/10.1007/s10334-011-0256-9
  2. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509-520 https://doi.org/10.1002/jmri.10304
  3. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 2006;60:353-366 https://doi.org/10.1016/j.ejrad.2006.06.025
  4. Jacquier A, Bucknor M, Do L, Robert P, Corot C, Higgins CB, et al. P846, a new gadolinium based low diffusion magnetic resonance contrast agent, in characterizing occlusive infarcts, reperfused ischemic myocardium and reperfused infarcts in rats. MAGMA 2008;21:207-218 https://doi.org/10.1007/s10334-008-0112-8
  5. Lemasson B, Serduc R, Maisin C, Bouchet A, Coquery N, Robert P, et al. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecularweight and macromolecular MR contrast media. Radiology 2010;257:342-352 https://doi.org/10.1148/radiol.10092343
  6. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-949 https://doi.org/10.2214/ajr.171.4.9762973
  7. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E, et al. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Invest Radiol 2001;36:445-454 https://doi.org/10.1097/00004424-200108000-00002
  8. Turetschek K, Floyd E, Shames DM, Roberts TP, Preda A, Novikov V, et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn Reson Med 2001;45:880-886 https://doi.org/10.1002/mrm.1117
  9. Fries P, Runge VM, Bücker A, Schürholz H, Reith W, Robert P, et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model. Invest Radiol 2009;44:200-206 https://doi.org/10.1097/RLI.0b013e31819817ff
  10. Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y, Park J, et al. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs 2013;31:1097-1106 https://doi.org/10.1007/s10637-012-9915-6
  11. Lee J, Bae S, Lee SH, Choi H, Kim YH, Kim SJ, et al. Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog. Bioorg Med Chem Lett 2010;20:6327-6330 https://doi.org/10.1016/j.bmcl.2010.05.060
  12. Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem 2010;53:6337-6354 https://doi.org/10.1021/jm1002414
  13. Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014;272:417-426 https://doi.org/10.1148/radiol.14131165
  14. Joo I, Kim JH, Lee JM, Choi JW, Han JK, Choi BI. Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors. Ultrasonography 2014;33:18-25
  15. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232 https://doi.org/10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
  16. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362 https://doi.org/10.1681/ASN.2006060601
  17. van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames DM, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-818 https://doi.org/10.1148/radiology.198.3.8628876
  18. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, et al. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 2010;20:2013-2026 https://doi.org/10.1007/s00330-010-1743-5
  19. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee JM, et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. MAGMA 2001;12:121-127 https://doi.org/10.1007/BF02668093

Cited by

  1. Assessment of therapeutic response in Crohn's disease using quantitative dynamic contrast enhanced MRI (DCE-MRI) parameters : A preliminary study vol.96, pp.32, 2017, https://doi.org/10.1097/md.0000000000007759
  2. Selection and Reporting of Statistical Methods to Assess Reliability of a Diagnostic Test: Conformity to Recommended Methods in a Peer-Reviewed Journal vol.18, pp.6, 2017, https://doi.org/10.3348/kjr.2017.18.6.888
  3. Contrast agents in dynamic contrast-enhanced magnetic resonance imaging vol.8, pp.26, 2015, https://doi.org/10.18632/oncotarget.16482